Hazel D Hill Multiple Myeloma Foundation

  • Home
  • Hazel D Hill Multiple Myeloma Foundation

Hazel D Hill Multiple Myeloma Foundation Multiple Myeloma is the second most common blood cancer. The Hazel D Hill Multiple Myeloma Foundation

Gatha Stephens, MBA MCHR
Professional Certified Anxiety Coach
Professional Certified Life Coach
Multiple Myeloma Cancer Coach
Volunteer: LGBTG Human Rights Org., American Heart Assoc., Multiple Myeloma Org., Ovarian Cancer Coalition, Member of the National PTA, Member of Wallin PTA
Former member of The Make a Wish Foundation, March of Dimes & United Way

20/09/2025

19/08/2025

In this year's issue, you can learn about exciting new investments we've made through the MMRF’s Myeloma Investment Fund®, the MMRC Horizon Clinical Trials Program, and so much more.

Digital Magazine - The 2025 Accelerator is a celebration of progress in myeloma research, yet it is also a sobering reminder of the important work needed to reach cures for all patients. Myeloma is still incurable, and so many patients are in desperate need of life-saving treatments. Our mission is to accelerate the path toward them, with programs and initiatives that only the MMRF can lead.

Cures are within reach, but this last mile is the most challenging – and the most critical. With your incredible support, we can continue driving significant impact for the patient community. And for that, we are truly grateful.

Sincerely,


Michael Andreini
President & CEO
Multiple Myeloma Research Foundation®

News from Healthtree Foundation for Multiple MyelomaMagnetisMM-32: A clinical trial for people with relapsed/refractory ...
10/04/2025

News from Healthtree Foundation for Multiple Myeloma
MagnetisMM-32: A clinical trial for people with relapsed/refractory multiple myeloma

Multiple myeloma is a blood cancer that forms in bone marrow tissue. Despite available treatments, at some point almost all patients relapse (get the cancer again), and the disease often becomes refractory (stops responding) to treatments.

MagnetisMM-32 is one of the clinical trials in the MagnetisMM program, a series of studies exploring elranatamab as a potential treatment for people with multiple myeloma.

MagnetisMM-32 is investigating whether elranatamab is more beneficial to people with relapsed/refractory cases of multiple myeloma, compared to other commonly used combination treatments. The study team is now enrolling volunteers to join the MagnetisMM-32 clinical trial.

14/03/2025

Address


Telephone

+17026865531

Website

Alerts

Be the first to know and let us send you an email when Hazel D Hill Multiple Myeloma Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Hazel D Hill Multiple Myeloma Foundation:

Shortcuts

  • Want your practice to be the top-listed Clinic?

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram